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Using antisense oligonucleotides 
for the physiological modulation 
of the alternative splicing of NF1 
exon 23a during PC12 neuronal 
differentiation
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Neurofibromatosis Type 1 (NF1) is a genetic condition affecting approximately 1:3500 persons 
worldwide. The NF1 gene codes for neurofibromin protein, a GTPase activating protein (GAP) and 
a negative regulator of RAS. The NF1 gene undergoes alternative splicing of exon 23a (E23a) that 
codes for 21 amino acids placed at the center of the GAP related domain (GRD). E23a‑containing 
type II neurofibromin exhibits a weaker Ras‑GAP activity compared to E23a‑less type I isoform. 
Exon E23a has been related with the cognitive impairment present in NF1 individuals. We designed 
antisense Phosphorodiamidate Morpholino Oligomers (PMOs) to modulate E23a alternative splicing 
at physiological conditions of gene expression and tested their impact during PC12 cell line neuronal 
differentiation. Results show that any dynamic modification of the natural ratio between type I and 
type II isoforms disturbed neuronal differentiation, altering the proper formation of neurites and 
deregulating both the MAPK/ERK and cAMP/PKA signaling pathways. Our results suggest an opposite 
regulation of these pathways by neurofibromin and the possible existence of a feedback loop sensing 
neurofibromin‑related signaling. The present work illustrates the utility of PMOs to study alternative 
splicing that could be applied to other alternatively spliced genes in vitro and in vivo.
Neurofibromatosis type 1 (NF1) is an autosomal dominant inherited neurocutaneous disease affecting about 
1:3500 persons worldwide, caused by mutations in the NF1  gene1. The most frequent clinical manifestations of 
NF1 are the presence of skin cafe au lait macules (CALMs), skin-fold freckling, iris hamartomas termed Lisch 
nodules and the development of multiple cutaneous neurofibromas, benign tumors originating in the periph-
eral nervous system (PNS). The presence of cognitive impairment and a high predisposition to develop other 
peripheral and central nervous system (CNS) tumors are also common and important clinical  manifestations1.
The NF1 gene is located in the pericentromeric region of chromosome 17, at 17q11.2, and spans about 280 Kb 
of genomic  DNA2. The gene is composed of 60 exons, 57 are constitutive exons and 3 are tissue-specific alter-
natively spliced exons (9a, 23a and 48a)3–5. This gene encodes for a protein termed neurofibromin. In its central 
region, neurofibromin contains a small domain (GAP-related domain, GRD) with a high sequence similarity 
to the family of GTPase activating proteins of Ras (Ras-GAPs)6–8. Neurofibromin acts as a negative regulator 
of Ras signaling by enhancing the intrinsic capacity of Ras to hydrolyze a phosphate of the Ras-bound GTP, 
turning this active form into an inactive Ras-GDP9. Activated Ras proteins interact with several downstream 
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effectors, regulating different signaling pathways, like the MAPK/ERK pathway, and cellular processes such as 
cell proliferation and  differentiation10.
Alternative splicing of exon 23a (E23a) of the NF1 gene generates two isoforms named type I and II. Splicing 
factors regulating this alternative splicing have been  investigated11–13. E23a lies within the GRD coding sequence 
and is constituted by 63 bp that encodes for 21 amino acids placed at the center of the GRD  domain5. Type II 
transcript contains E23a and exhibits a ten-fold lower Ras-GAP activity compared to E23a-less type I  isoform14–16. 
Thus, type II isoform is a weaker negative regulator of Ras than type I. Alternative splicing is a major source of 
proteome diversity and a key regulator of physiological processes, like neuronal branching and differentiation, 
brain development,  etc17,18. However, the physiological relevance of alternative splicing is still largely unknown. 
Likewise, the impact on cell physiology of the expression and regulation of NF1 type I/II isoforms is still not 
completely understood. Many studies have characterized the expression of both isoforms in different tissues 
and organs (even in different organ parts), developmental stages and in  tumors5,19–27. While type II isoform is 
predominantly expressed in most adult tissues, type I isoform has been found expressed in neurons of the CNS at 
certain developmental stages and in  adulthood5,19,23–25,27. The switch from type II to type I has also been charac-
terized upon the induction of neural differentiation of PC12 cells by nerve growth  factor28. The increase in GAP 
activity due to the higher expression of neurofibromin type I isoform correlates with a down-regulation of Ras 
activity during PC12 neurite  elongation15, and also in embryonic stem cell-derived  neurons29. Neurofibromin has 
also been shown to regulate cAMP-dependent signaling  pathways30,31 and PC12 neuronal differentiation is in fact 
dependent on the interplay of both the MAPK/ERK signaling and the cAMP/PKA  signaling32–34. Finally, E23a has 
also been studied in relation to NF1 clinical manifestations. Genetically engineered mouse models either  lacking35 
or retaining  E23a36 recapitulate NF1 learning and cognitive disabilities. NF1-dependent activation of cAMP/
PKA signaling has also been demonstrated to be essential for mediating Drosophila learning and  memory37.
Antisense oligonucleotides (ASOs) have been used to inhibit gene expression and to modify splicing 
 outcomes38–41. For instance, ASOs have been successfully used to totally or partially overcome the impact of 
nonsense, frame-shift and deep intronic mutations at the expression  level42–44. However, the use of ASOs to 
modulate alternatively spliced exons has almost not been  explored45–47. Among different types of ASOs, Phospho-
rodiamidate Morpholino Oligomers (PMOs) have highly desirable molecular properties that make them suitable 
for splicing modulation. In PMOs, the deoxyribose sugar is replaced with a six-member morpholino ring, and 
the phosphodiester inter-subunit bonds are replaced with phosphorodiamidate linkages, a structure that provides 
a high-targeting specificity, stability, low toxicity and resistance to  nucleases48, assuring the maintenance of a 
good long-term activity within the cell. PMOs can be delivered into cultured cells using different transfection 
agents, like the peptide-mediated delivery reagent Endo-Porter (EPEI) that provides good transfection efficien-
cies while preventing cell  toxicity49,50.
In this work we designed and used PMOs to modulate the alternative splicing of E23a of the NF1 gene in the 
PC12 neuronal differentiation system. We show that PMOs are useful tools to affect and study alternative splicing 
of an RNA of interest by forcing the exclusion or inclusion of targeted exons, without the need for endogenous 
gene editing and while maintaining the physiological levels of gene expression. Furthermore, PMO-mediated 
targeted splicing changes can be used to study the role of individual isoforms in dynamic processes such as dif-
ferentiation, as demonstrated here by using NF1 alternative splicing as a model.
Results
Cell‑based systems to study the alternative splicing of exon 23a (E23a) of the NF1 gene. To 
design and test the use of Phosphorodiamidate Morpholino Oligomers (PMOs) for modulating the alterna-
tive splicing of exon 23a (E23a) of the NF1 gene, we first evaluated the potential use of different cell-based 
model systems: two neuronal differentiation systems (pheochromocytoma-derived PC12 cells and embryonic 
hippocampal H19-7/IGF-IR cells) and nerve-derived Schwann cell (SC) cultures from an NF1 individual. PC12 
cells can be stimulated to differentiate into sympathetic-like neurons in the presence of Nerve Growth Fac-
tor (NGF)51. The use of NGF triggers cell division arrest, neurite extension and increases synthesis of several 
 neurotransmitters52. In addition, during differentiation there is a partial switch in Nf1 isoforms from type II 
transcripts (E23a included) to the expression of type I transcripts (E23a excluded)28. We analyzed the extent and 
dynamics of E23a alternative splicing during PC12 differentiation in our hands (Fig. 1A). We also analyzed the 
alternative splicing of E23a during the differentiation of rat embryonic hippocampal H19-7/IGF-IR. Upon the 
addition of basic Fibroblast Growth Factor (bFGF) and a temperature increase, H19-7/IGF-IR cells extended 
neurites and changed morphology similarly to PC12 differentiating cells (Fig. 1B). In this cell line, the switch 
from type II to type I isoform was already observed at 24 h after bFGF-triggered differentiation (Fig. 1B). Finally, 
we also evaluated E23a alternative splicing in nerve-derived primary Schwann cells (SCs) after a continuous 
exposure to high concentrations of forskolin, an elevator of cAMP through adenylate cyclase stimulation. We 
observed a slight increase in type II isoform expression in differentiated SCs (Fig. 1C), in accordance with previ-
ous  results4. With these analyses, we evidenced that the alternative splicing of E23a participates in a different 
manner in distinct cell differentiation processes. To test the applicability of PMOs on E23a alternative splicing 
analysis, we selected the PC12 differentiation model, as it was the most amenable cell culture system. However, it 
should be noted that the PC12 differentiation system is very sensitive to the specific conditions of the cells (cell 
density, media, manipulation, etc.) and any slight change in these conditions affect the degree of differentiation. 
We observed different PC12 differentiation outputs, regarding cell morphology and degree of Nf1 alternative 
splicing, in independent experiments. However, within each experiment, samples preserved the same relative 
relationship, and quantification of the degree of E23a splicing facilitated a relative comparison.
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Design and use of PMOs to induce the skipping or inclusion of E23a while maintaining physio‑
logical NF1 levels. We designed and tested in vitro antisense PMOs to induce the skipping (PMO-SkpE23a) 
or the inclusion (PMO-IncE23a) of E23a (Figs. 2 and 3). PMO-SkpE23a was designed to specifically bind to the 
acceptor-splicing site of E23a within the intron–exon junction (Fig. 2A). We first performed a dose–response 
assay in the highly transfectable HEK293T cell line (Fig. 2B). We tested different concentrations of PMO and 
successfully induced almost complete E23a skipping at lowest concentration tested of PMO-SkpE23a after 24 h. 
After adjusting the concentration for PC12 cells, we then tested the efficacy of 20 µM concentration of PMO-
SkpE23a to induce E23a skipping in a time course experiment, achieving high levels of E23a skipping already 
after 24-48 h (Fig. 2C). We also analyzed by RT-qPCR the impact of PMO-SkpE23a on E23a skipping compared 
to the effect of NGF treatment after 72 h (Fig. 2D) and in the endogenous expression of Nf1 (Fig. 2E). We finally 
tested the specificity of the designed PMO-SkpE23a on E23a modulation by comparing its skipping efficacy 
with that of a non-targeting PMO control (NTC) (Fig. 2F). Results indicated that PMO-SkpE23a treatment was 
able to induce E23a skipping in a specific manner even at higher levels than NGF alone, while maintaining the 
endogenous expression levels of Nf1.
The PMO-IncE23a was designed to enhance the inclusion of E23a, a more complicated task than forcing the 
skipping of an exon, due to the high number of splicing factors and the complex regulation of alternatively-spliced 
exons. We first analyzed the degree of conservation of the intronic sequences surrounding E23a compared to 
adjacent exons (Fig. 3A). We observed that E23a had a highly conserved intronic region at 5′- and 3′- expanding 
further away from the coding sequence compared to adjacent exons, as previously  described53 (Fig. 3A). Non-
coding conservation has also been described in the intronic regions adjacent to other important tissue regulated 
Figure 1.  Analysis of the alternative splicing of E23a of the NF1 gene in different cellular models. (A) Top: 
Phase-contrast images of PC12 cells without (left) or with (right) NGF. Bottom: Schematic representation of 
E23a alternative splicing during PC12 neuronal differentiation and RT-PCR time course analysis of the switch 
from Nf1 type II (+E23a) to type I (-E23a) transcripts after NGF addition to PC12 cells. (B) Top: Phase contrast 
images of H19-7/IGF-IR cells without (left) or with (right) differentiation conditions. Bottom: RT-PCR analysis 
of Nf1 type II (+E23a) switch to type I (-E23a) transcript at 24 h is shown. (C) Top: Phase contrast images of 
proliferating nerve-derived primary Schwann cells (left) and differentiating (right) conditions. Bottom: RT-PCR 
analysis of NF1 isoform switch is illustrated. For all phase-contrast images scale bar is 30 μm. E23a splicing was 
quantified as the percent spliced-in (PSI) (standard deviation in parentheses). All supporting uncropped gels 
can be found in Supplementary Fig. S1.
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Figure 2.  Design of a PMO to force the skipping of E23a and experimental conditions set up. (A) Schematic 
diagram of E23a skipping strategy using PMO-SkpE23a (in red) targeting its acceptor splice site. (B) Dose–
response analysis at different PMO-SkpE23a concentrations in HEK293T cells measured by RT-PCR. (C) Time 
course experiment using PMO-SkpE23a in PC12 cells measured by RT-PCR. (D) Relative mRNA isoform 
type I (-E23a) expression normalized by the total Nf1 expression at 72 h, measured by RT-qPCR. (E) Total Nf1 
expression levels at 72 h after PMO addition, measured by RT-qPCR. (F) Expression of Type II/I isoforms in 
PC12 cells treated with transfection agent (TA), a non-targeting control PMO and PMO-SkpE23a, 72 h after 
PMO addition and measured by RT-PCR. For all plots, bars indicate Mean ± SEM. NRE: Normalized Relative 
Expression. All supporting uncropped gels can be found in Supplementary Fig. S2. E23a splicing was quantified 
as the percent spliced-in (PSI) (standard deviation in parentheses).
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 exons54–56. Within these conserved intronic regions, we set out to determine the potential binding sites for E23a 
splicing factors. An in silico analysis identified an enrichment in AU-rich and UG-rich sequences, binding 
sites for Hu and CELF proteins, E23a skipping  promoters11, and TIA-1/R or MBNL proteins, E23a inclusion 
 promoters12,13 (Fig. 3B). We selected three regions within the 5′ intronic sequence of E23a that concentrated most 
of the binding factors that promote E23a exclusion (mainly protein families Hu and CELF). These regions were 
named Conserved Splicing Regions (CSRs). We designed three distinct PMOs to bind to these regions to puta-
tively block the binding of these factors. We then tested their performance in PC12 cells after NGF addition, to 
assess their capacity to block NGF-triggered E23a skipping. Some of the PMOs induced the skipping rather than 
the inclusion of E23a, but one of them, targeting CSR II, was able to retain E23a despite NGF treatment of PC12 
cells (Fig. 3C). We measured this exon retention quantitatively by RT-qPCR (Fig. 3D), and also confirmed that 
the use of PMO-IncE23a was not significantly altering the endogenous expression of the Nf1 gene (Fig. 3E). The 
different effect on E23a splicing of the three tested PMOs, the specific skipping capacity of PMO-SkpE23a and the 
lack of E23 splicing effect of an NTC PMO, provided different evidenced of the specificity of the designed E23a 
PMOs. NTC had no effect on E23a splicing (Fig. 2F; Supplementary Fig. S5A) neither changed the morphology 
of PC12 cells (Supplementary Fig. S6) or signaling pathways (Supplementary Figs. S7 and S12A,B,C), behaving 
as the addition of TA only. However, RNA-seq analysis of NTC PMO treated cells, revealed a certain change in 
gene expression compared to TA alone (data not shown). Given the control on E23a splicing specificity provided 
by the two antagonistic splicing-regulating E23a PMOs, we decided to use TA alone as control conditions.
Impact of E23a alternative splicing modulation by PMOs on NGF‑mediated PC12 neuronal 
differentiation. After designing and setting up of E23a PMOs, we tested their effect on PC12 neuronal dif-
ferentiation. As determined by our initial time-course experiment (Fig. 2C), PMO-SkpE23a treatment had an 
earlier and larger effect on the levels of E23a skipping (i.e. a type II to type I switch) compared to NGF treatment 
alone in PC12 cells (Fig. 1A). We first evaluated the percentage of PC12 differentiated cells according to neurite 
generation 72 h after NGF treatment (Fig. 4A,B). Differentiated cells were considered when at least one neurite 
acquired a length equal or longer than the cell body diameter (see M&M section). PMO-SkpE23a treatment 
reduced the percentage of differentiated cells and on those differentiated, reduced the formation of multiple 
and branched neurites (Fig. 4A,B). Furthermore, the induction of E23a alternative splicing in the absence of 
NGF did not induce neuronal differentiation of PC12 cells. In concordance with the reduced and altered neurite 
formation, PMO-SkpE23a also reduced the expression of the neuronal markers Gap43, Mmp3 and Dusp6 and 
the enzymatic activity of NADH-dehydrogenase (Fig. 4C) on NGF treated cells. We also used PMO-IncE23a 
to avoid NGF-induced isoform switch from Type II (+E23a) to Type I (-E23a). Again, we evaluated PC12 dif-
ferentiation 72 h after NGF treatment. The addition of PMO-IncE23a did not change the percentage of cells that 
generated neurites but clearly reduced neurite thickness (Supplementary Fig. S5B) and their apparent robustness 
compared to NGF treatment alone (Fig. 5A,B). Consistent with an altered differentiation, expression of neuronal 
markers was also altered (Fig. 5C) although not to the same extent as using PMO-SkpE23a.
To further explore the molecular consequences of NF1 alternative splicing modification by PMOs on PC12 
neuronal differentiation, we analyzed the status of the MAPK/ERK and cAMP/PKA signaling pathways. Con-
sistent with a higher RAS-GAP activity of Type I (-E23a) isoform, we identified reduced levels of ERK 1/2 
phosphorylation in PC12 cells treated with PMO-SkpE23a and with or without NGF, compared to their respec-
tive controls, 72 h post NGF addition (Fig. 6A). We did not observe significant changes in the levels of ERK 
phosphorylation in PMO-IncE23a treated cells compared to controls (Fig. 6A). We also measured the activity of 
the cAMP/PKA signaling pathway by western blot of phosphorylated PKA α/β (P-PKA α/β). P-PKA α/β levels 
slightly increased in PC12 cells upon NGF treatment. In the presence of PMO-SkpE23a, the levels of P-PKA α/β 
were higher upon NGF treatment than in NGF-treated PC12 cells alone (Fig. 6B). PMO-IncE23a treatment had 
no effect on PKA activation on PC12 cells (Fig. 6B).
Taken together, these results indicated that any alteration of the natural NF1 isoform switch produced by NGF 
in PC12 cells altered their neuronal differentiation phenotype morphologically, at the level of neuronal marker 
expression and on the regulation of NF1-related signaling pathways.
Dynamic modification of E23a alternative splicing by PMOs in PC12 neuronal differentia‑
tion. One of the advantages of using PMOs to study the impact of alternative splicing on cell physiology is 
their flexibility of use: different concentrations of PMO with different quantitative effects on splicing can be used; 
its treatment can be reversed; its addition can be performed at different time points using the same cells. This 
flexibility facilitates the study of physiological processes in a dynamic way. To test this, we designed an experi-
ment in which we analyzed the effect of inducing the alternative splicing of E23a before adding the biological 
stimulus (NGF) responsible for the natural NF1 alternative splicing during PC12 cells differentiation (Supple-
mentary Fig. S8). By inducing type I isoform (-E23a) before NGF treatment, we were conferring the maximum 
Ras-GAP activity to NF1 expression before the induction of PC12 differentiation. To have a more complete 
experimental framework, we also designed a new set of PMOs (PMO-SkpE14; Supplementary Fig. S9), to force 
the skipping of an out-of-frame exon, exon 14 (E14). By doing this, a premature stop codon was formed, induc-
ing the nonsense mediated decay (NMD) machinery, highly reducing neurofibromin expression (Supplemen-
tary Fig. S9D) and thus, expecting a reduction in the overall Ras-GAP activity.
PC12 cells were treated with PMO-SkpE23a and with PMO-SkpE14 24 h before NGF treatment and we 
analyzed neuronal differentiation capacity in a time course at morphological, gene expression and signaling 
levels. Forcing the switch from type II to type I NF1 isoform before NGF treatment reduced the percentage of 
differentiated cells and its morphological complexity, with neurites being straighter, thicker and less branched 
(Fig. 7A,B) similarly to adding PMO-SkpE23a at the same time as NGF (Fig. 4A,B). In addition, the expression 
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of neuronal markers was also reduced (Fig. 7C). A similar but enhanced alteration on PC12 differentiation was 
obtained when cells were treated with NGF and PMO-SkpE14, with a decreased percentage of differentiated 
cells, with a reduced number of neurites, being less complex and longer (Fig. 7A,B; Supplementary Fig. S11A). In 
fact, differentiated cells showed an increase in varicosite thickness along the neurite extensions (Supplementary 
Fig. S11B). The expression of neuronal differentiation markers was also altered (Fig. 7C). However, PMO-SkpE14 
elicited a significant increase in early apoptotic cells that was partially reverted by the NGF-induced cell cycle 
arrest of PC12 cells (Supplementary Fig. S11C). Thus, results regarding the use of PMO-SkpE14 have to be cir-
cumscribed to the cells that did not undergo apoptosis, being biased in this regard.
In addition, we analyzed the status of the MAPK/ERK and cAMP/PKA signaling pathways in these experi-
mental conditions (Fig. 8 and Supplementary Fig. S12), adding also a condition in which PMO-SkpE23a was 
included at the same time as NGF, for comparison purposes. As before (Fig. 6A) P-ERK 1/2 levels were signifi-
cantly reduced when PMO-SkpE23a was added at the same time as NGF along the time-course experiment, 
according to an increased Ras-GAP activity. In clear contrast and surprisingly, in conditions where PMO-
SkpE23a was added 24 h before NGF, ERK phosphorylation levels were similar to control cells treated with NGF, 
reaching levels at 72 h similar to those in PC12 cells treated with PMO-SkpE14, with low levels of neurofibromin 
and thus low Ras-GAP activity (Fig. 8A). Furthermore, we also measured PKA phosphorylation levels at 48 h 
after NGF treatment. When PMO-SkpE23a was added at the same time as NGF there was a clear increase in 
PKA phosphorylation (Fig. 8B and Supplementary Fig. S12D) as observed previously (Fig. 6B). Again, this result 
contrasted with conditions where PMO-SkpE23a was added 24 h before NGF, in which PKA was activated below 
control levels, similarly to the effect triggered by PMO-SkpE14, in conditions with depleted neurofibromin 
(Fig. 8B). These results in one hand supported the view that there was an inverse relationship between the func-
tion of neurofibromin and the regulation of either the MAPK/ERK pathway or the cAMP/PKA pathway during 
PC12 neuronal differentiation. On the other hand, they suggested an apparent desensitization of neurofibromin 
function if the isoform switch towards a higher GAP activity (E23a-less type I isoform) was produced before 
the addition of NGF. Consistent with this view, RNA-seq analysis of these conditions (Supplementary Fig. S13) 
revealed a transient transcriptional activation of genes due to PMO-SkpE23a addition alone (Supplementary 
Fig. S13A). Many of these genes were NGF-response genes (Supplementary Fig. S13B). This differential global 
expression status at the time of NGF addition may explain the differences in signaling and physiological readouts 
in PC12 cells under these two different conditions, and may show a pathway feedback triggered by NGF and 
dependent on neurofibromin function. At the same time, these results highlight the importance of the timing at 
which genetic perturbations are made in this PC12 neuronal differentiation model system, since although being 
the exact same system, results and their interpretation can be very different.
Discussion
The present work illustrates the utility of PMOs to study alternative splicing. PMOs allow the preservation 
of physiological gene expression conditions and can be used in a highly flexible way, facilitating the study of 
dynamic processes and partially overcoming static genetic methods. In addition, results obtained by applying 
PMOs to the study of the alternative splicing of NF1 E23a highlight the importance of a precise quantitatively and 
time-dependent regulation of E23a splicing along the neuronal differentiation process. Finally, it constitutes an 
interesting example of how the alternative splicing of a single gene can influence cell fate by the fine, coordinated, 
and time-dependent regulation of different signaling pathways.
Antisense technology has been scarcely used for exploring the biological processes related to the natural alter-
native splicing of  genes45–47. In this work, all designed PMOs had an incomplete but reasonable efficiency regard-
ing the degree of induced exon skipping or inclusion already 24 h after PMO treatment. The use of PMOs to force 
exon inclusion has been explored to a lesser extent than for the skipping of an  exon57–59 and even lesser in the 
context of alternative splicing. The analysis of intronic sequence  conservation53, as well as previous information 
on both cis-acting sequences and trans-acting factors (Hu and CELF; and TIA-1/R and MBNL proteins)11–13,60 
were of especial importance for the identification of a PMO that forced the inclusion of E23a in conditions of 
NGF-triggered E23a skipping. Moreover, an advantage of using E23a PMOs was the successful modulation of 
E23a splicing without significantly altering the physiological levels of Nf1 mRNA expression, in contrast to the 
use, for instance, of over expression plasmids. Another advantage of PMOs is its flexible use regarding the time 
of exposure and its duration, its reversibility and the concentration used in relation to the degree of splicing 
modulation. This flexibility allowed us to study the impact of E23a alternative splicing in PC12 neuronal differ-
entiation overcoming static genetic methods, such the generation of genetically modified cell  lines29 and being 
able to observe more subtle and complex regulations, such as the feed-back regulation of signaling pathways 
(see below). The developed PMOs can be applied to other NF1 in vitro and in vivo models to better understand 
Figure 3.  Design of a PMO to force inclusion of E23a and experimental conditions set up. (A) Analysis of 
the degree of sequence conservation of E23a, E24 and E25 of the NF1 gene and adjacent intronic regions. (B) 
Splicing factors predicted by SpliceAid2 to bind the 5´ intronic region of E23a. Colored boxes represent three 
Conserved Splicing Regions (CSR) selected to design a PMO to block E23a skipping while preserving a correct 
splicing. (C) Type II and type I Nf1 isoform expression levels analyzed by RT-PCR using three PMO’s targeting 
CSR I, II & III and their combination (COMB), 72 h after PMO and NGF treatment. PMO targeting CSR II 
(highlighted in yellow) was selected as PMO-IncE23a. E23a splicing was quantified as the percent spliced-in 
(PSI) (standard deviation in parentheses). Supporting uncropped gel can be found in Supplementary Fig. S3. 
(D) Relative isoform type I (-E23a) expression normalized by the total Nf1 expression by RT-qPCR. (E) Total 
Nf1 expression levels at 72 h after PMO addition. NRE: Normalized Relative Expression (Rpl29 and Rpl19 were 
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the role of alternative E23a splicing while preserving physiological conditions. Furthermore, the same type of 
approach can be applied to other alternatively spliced genes in the context of other biological conditions.
PC12 neuronal differentiation is a complex physiological process that implicates the activation of a network 
of signal transduction pathways triggered by NGF. These pathways integrate into a transcriptional response that 
regulate both signaling and morphological and physiological  changes32–34,51,61. We tested the utility of designed 
PMOs to study the implication of NF1 E23a alternative splicing in neuronal differentiation. We first evidenced 
that mimicking the switch from type II to type I neurofibromin by PMO-SkpE23a alone, without NGF addition, 
did not induce PC12 cells to undergo neuronal differentiation. We also observed that the use of each NF1 E23a 
PMO (PMO-SkpE23a and PMO-IncE23a) elicited a different perturbation of the differentiation process, although 
in both cases implicated the formation of neurites (either in number, complexity or robustness), the alteration of 
the expression of neuronal differentiation markers, and the deregulation of both MAPK/ERK and cAMP/PKA 
pathways. Despite the different elicited responses, the use of NF1 E23a PMOs clarified that any quantitative or 
time-dependent alteration of the NGF-triggered natural switch from type II to type I neurofibromin, impacted 
on the correct neuronal differentiation of PC12 cells at signaling, gene expression and morphological levels.
Regulatory networks driving complex and dynamic physiological responses, such as neuronal differentiation, 
are difficult to study. The role of NF1 E23a alternative splicing on neuronal differentiation has been studied using 
Figure 4.  Impact of forcing E23a skipping using PMO-SkpE23a on NGF-induced PC12 neuronal 
differentiation. (A) Top: Representative images of a double immunofluorescent staining of NGFR (red) and 
α-tubulin (green) of PC12 cells after 72 h at different experimental conditions (scale bar = 40 μm). Bottom: 
Box specifying the different experimental conditions and the type II/I isoform expression ratio measured by 
RT-PCR. E23a splicing was quantified as the percent spliced-in (PSI) (standard deviation in parentheses). 
Supporting whole gel image can be found in Supplementary Fig. S4. (B) Time course analysis of the percentage 
of differentiated cells per field for each experimental condition. Each point represents the Mean ± SEM. *P < 0.05, 
paired t-test versus cells treated only with NGF. (C) Expression of the neuronal differentiation markers Dusp6, 
Gap43, Mmp3 analyzed by RT-qPCR and the enzymatic activity of NADH-dehydrogenase at the different 
experimental conditions set. NRE: Normalized Relative Expression (Rpl29 and Rpl19 were used as reference 
genes). NAV: Normalized Absorbance Values. Bars indicate Mean ± SEM. *P < 0.05, **P < 0.01, paired t-test 
versus cells treated only with NGF. TA: transfection agent.
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the overexpression of specific isoforms or generating mouse cell lines with both Nf1 alleles with or without  E23a29. 
However, non-physiological or static perturbations may not be the best tools for a fine analysis. Although not 
perfect, PMOs permit a greater flexibility in system perturbation. For instance, PMOs allowed us to force the 
skipping of E23a towards type I neurofibromin, with the highest Ras-GAP activity, before the addition of NGF 
to PC12 cells. In these initial conditions, after NGF addition we expected a reduced level of ERK1/2 activation, 
at least similar to conditions in which NGF and PMO-SkpE23a were added simultaneously. Surprisingly, the 
levels of ERK1/2 phosphorylation were similar to NGF-treated control cells and comparable to those exhibited 
by PC12 cells in which neurofibromin was knockdown by PMO-SkpE14 (Fig. 8). Similarly, when PMO-SkpE23a 
was added 24 h before NGF, PKAα/β activation was reduced, as in PMO-SkpE14-treated cells, and not activated 
as in conditions where NGF and PMO-SkpE23a were added simultaneously. All these results seemed to point 
to an apparent desensitization of neurofibromin function in PC12 cells if exposed to neurofibromin with a high 
Ras-GAP capacity before NGF addition and to a hypothetical feed-back loop to sense pathway activation. Con-
sistent with this hypothesis, in PC12 cells exposed for 24 h to PMO-SkpE23a, we identified an upregulation of 
NGF response genes. Thus, these cells had a different NGF-related transcriptional profile at the moment NGF 
was added to the media. Further experiments are needed to confirm the existence of this putative feed-back loop, 
but PMO flexibility allowed to alert about its possible existence.
MAPK/ERK sustained  activation62 and its crosstalk with cAMP-dependent signaling  pathways33,34,61 are key 
events in PC12 neuronal differentiation. Neurofibromin participates of both  pathways63 and the time-course 
dynamics of type II to type I isoform switch in PC12 differentiation correlates with the level of RAS  activation15. 
Nevertheless, the whole picture is still incomplete. In the present work we performed a limited analysis of 
Figure 5.  Impact of forcing E23a inclusion using PMO-IncE23a on NGF-induced PC12 neuronal 
differentiation. (A) Top: Representative images of a double immunofluorescent staining of NGFR (red) 
and α-tubulin (green) of PC12 cells after 72 h at different experimental conditions (scale bar = 30 μm). 
Bottom: Box specifying the different experimental conditions and the type II/I isoform expression ratio 
measured by RT-PCR. E23a splicing was quantified as the percent spliced-in (PSI) (standard deviation in 
parentheses). Supporting whole gel images can be found in Supplementary Fig. S5A. (B) Time course analysis 
of the percentage of differentiated cells per field for each experimental condition. Each point represents 
the Mean ± SEM. Complementary neurite thickness analysis can be found in Supplementary Fig. S5B. (C) 
Expression of the neuronal differentiation markers Dusp6, Gap43 and Mmp3 at the different experimental 
conditions set, analyzed by RT-qPCR. NRE: Normalized Relative Expression (Rpl29 and Rpl19 were used as 
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Figure 6.  Effect of E23a skipping or inclusion by PMO treatment on the activation of ERK and PKA during 
NGF-induced PC12 neuronal differentiation. (A) Western blot analysis and quantification of P-ERK1/2, total 
ERK1/2 and alpha-tubulin levels after forcing E23a skipping (PMO-SkpE23a) or inclusion (PMO-IncE23a) at 
72 h after NGF treatment at different experimental conditions summarized in a box below each graph/western. 
***P < 0.001, paired t-test versus cells treated only with NGF. Bars indicate Mean ± SEM. (B) Western blot 
analysis and quantification of P-PKAαβ, total PKAαβ and β-actin, at the same conditions as in (A), but 48 h 
after NGF treatment. *P < 0.05, paired t-test versus cells treated only with NGF. Bars indicate Mean ± SEM. TA: 
transfection agent. Supporting whole gel images can be found in Supplementary Fig. S7.
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pathway activation (e.g.: no direct measurement of cAMP or Ras-GTP levels). However, despite its limitations, 
results obtained with the use of E23a PMOs suggest some new insights into the regulation of signaling path-
ways by neurofibromin. In particular, they suggest a coordinated and opposite regulation of the MAPK/ERK 
and cAMP/PKA pathway. The addition of PMO-SkpE23a together with NGF resulted in a reduced activation 
of MAPK/ERK pathway, consistent with an increased neurofibromin GAP activity. But this co-treatment also 
induced an upregulation of the cAMP/PKA signaling. On the contrary, forcing type II isoform (+E23a) with less 
neurofibromin GAP activity, resulted in a similar ERK activation and a clear downregulation of the cAMP/PKA 
pathway. These results clearly illustrated a coordinated an opposite regulation of both pathways. Further analysis 
is required to understand how both neurofibromin isoforms differentially regulate cAMP/PKA signaling. All 
together our results suggest that for a correct NGF-triggered PC12 neuronal differentiation, the time-dependent 
fine regulation of the NF1 E23a alternative splicing is important. Neurofibromin activity resulting from the NF1 
E23a alternative splicing regulates both MAPK/ERK and cAMP/PKA signaling pathways in an opposite manner, 
decreasing MAPK/ERK and increasing cAMP/PKA activity, coordinating both signals in a time-dependent way 
along the differentiation process.
Figure 7.  Impact of inducing NF1 isoform switch before NGF-triggered differentiation of PC12 cells. (A) 
Top: Representative images of a double immunofluorescence staining of NGFR (red) and α-tubulin (green) 
of PC12 cells after 48 h at different experimental conditions (scale bar = 62 μm). Bottom: Box specifying the 
different experimental conditions and either the type II/I isoform expression ratio or the levels of E14 skipping 
measured by RT-PCR. For detection of E14 skipping, cells were treated with puromycin. E23a and E14 splicing 
was quantified as the percent spliced-in (PSI) (standard deviation in parentheses). Supporting whole gel images 
can be found in Supplementary Fig. S10. (B) Time course analysis of the percentage of differentiated cells per 
field for each experimental condition. Each point represents the Mean ± SEM. *P < 0.05, **P < 0.01, paired t-test 
versus cells treated only with NGF. (C) Expression of neuronal differentiation markers Dusp6, Gap43, Mmp3 
at different experimental conditions, analyzed by RT-qPCR. NRE: Normalized Relative Expression (Rpl29 and 
Rpl19 were used as reference genes). Bars indicate Mean ± SEM. *P < 0.05, **P < 0.01, paired t-test versus cells 
treated only with NGF. TA: Transfection agent.
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Finally, cAMP/PKA signaling has been shown to be essential for mediating Drosophila learning and 
 memory31. At the same time, genetically engineered mouse  lacking35 or retaining  E23a36 recapitulate NF1 learn-
ing and cognitive disabilities, similar to those of NF1(+/−)  mice64–66, and also similar to the ones observed in NF1 
patients. The designed PMOs could be used in an in vivo format, either by a direct delivery or in combination 
with agents that facilitate to cross the blood–brain  barrier67,68, to test their impact on learning and memory of 
WT and NF1(+/−) mice.
The present work shows the potential of using PMOs to study alternative splicing, since they preserve physi-
ological gene expression conditions and can be used in a quite flexible way in contrast to static genetic methods. 
When applied to the study of the role of NF1 E23a alterative splicing in PC12 neuronal differentiation, PMOs 
allowed to clarify the precise quantitatively and time-dependent regulation of E23a splicing along the neuronal 
differentiation, suggested a potential feed-back loop regulation in the NGF-triggered neurofibromin-dependent 
signaling, and showed the coordinated and opposite regulation of the MAPK/ERK and cAMP/PKA signaling 
pathways by neurofibromin.
Figure 8.  Effect on ERK and PKA activation of inducing NF1 isoform switch before NGF-triggered 
differentiation of PC12 cells. (A) Time course expression analysis by Western blot of P-ERK1/2 levels 
normalized to total ERK1/2 levels using different PMOs and PMO conditions. Differences between PMO-
SkpE23a added 24 h before NGF treatment (-24 h), PMO-SkpE23a and PMO-SkpE14 added at the same time 
as NGF treatment were evaluated by paired t-test versus cells treated only with NGF. Each point represents the 
Mean ± SEM. ***P < 0.001. (B) Expression analysis by Western blot and quantification of P-PKA and total PKA 
using different PMOs and PMO conditions. Differences were evaluated by paired t-test versus cells treated only 
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Materials and methods
Cell culture. PC12 cells (ATCC CRL-1721) were grown on Collagen IV-coated dishes (25 μg/ml) and main-
tained in RPMI 1640 medium, supplemented with 10% fetal bovine serum (complete RPMI medium) at 37ºC 
in 5% of  CO2. For the NGF treatment, PC12 were plated on Collagen IV-coated dishes in complete medium 
for 24 h and then switched to RPMI with 1% fetal bovine serum and 50 ng/ml NGF (Promega). H19-7/ IGF-IR 
(ATCC CRL-2526) were maintained in DMEM supplemented with 10% fetal bovine serum, 200 mg/ml of G418 
(Calbiochem) and 1 mg/ml of puromycin (Sigma-Aldrich) at 33ºC in 5%  CO2. For differentiation experiments, 
H19-7/IGF-IR cells were grown to confluence and then cells were washed extensively and shifted to the non-
permissive temperature of 39ºC with 5% of  CO2 in DMEM medium supplemented with 1X N2 (Calbiochem) 
and 10 ng/mL bFGF (Invitrogen). Primary Schwann cells previously isolated from an NF1 patient nerve biopsy, 
were thawed and cultured on Poly-L-Lysine (0.1 mg/mL) and laminin (4 µg/mL) coated plates in Schwann Cell 
Media (SCM) + forskolin, and incubated at 37 °C and 10%  CO2 for 24 h as described  previously69. Then medium 
was replaced by SCM without forskolin for 2 days. For proliferative conditions, cells were cultured in SCM + for-
skolin for 1 day and replaced with SCM for 2–3 days, repeating this process in cycles. For differentiation condi-
tions, cells were cultured with SCM + forskolin constantly for 5 days.
RNA extraction, quantification and reverse transcription (RT). Total RNA was extracted using 
Tripure Isolation Reagent (Roche). Quality and quantity were assessed using NanoDrop spectrophotometer and 
gel electrophoresis analysis. For an accurate quantification, size and integrity of the RNA was determined with 
Bioanalyzer (RNA Nano Assay: 25–500 ng/µl), according to manufacturer instructions. Reverse transcription of 
1-3 μg of RNA was performed with SuperScript II First-Strand Synthesis System (ThermoFisher Scientific) with 
random hexamers (Life Technologies, SA) following manufacturer’s instructions.
E23a alternative splicing analysis and Nf1 expression levels. For the quantification of E23a alterna-
tive splicing (Figs. 2D and 3D) and Nf1 expression levels (Figs. 2E and 3E) RT-qPCR analysis was performed. 
Primers used are summarized in Supplementary Table S2. In particular, primers were designed to specifically 
detect exon 23a skipping (exon 23–2/24 boundary) and inclusion (exon 23–2/23a boundary). In addition, a pair 
of primers was used to detect the expression of constitutive exon 3, to assess global Nf1 expression. Expression 
levels were normalized using Rpl29 and Rpl19 reference  genes70. RT-qPCR was performed using SYBR Green I 
master mix (Thermo Fisher Scientific) according to manufacturer’s instructions. Reactions were run on Light 
Cycler 480 II Real Time PCR system (Roche). Conditions for amplification were as follows: 95 °C for 10 min; 40 
cycles of 95 °C for 10 s, 59 °C for 30 s, and 72 °C for 20 s; and finally, a melting curve of 95 °C for 5 s and 65ºC 
for 1 min.
Monitorization of E23a alternative splicing status in all other experiments was performed by RT-PCR using 
1 μl of cDNA and running PCR products on a 2% agarose gel. Primers (forward E23-2 and reverse E25, Supple-
mentary Table S2) and PCR conditions were based in the work of Metheny L et al. (1996)28 in a 25 cycles reaction. 
Percent spliced-in (PSI) was calculated as the proportion of type II isoform versus total expression, using band 
intensities and according to this formula: (PSI) = Type II Isoform/(Type II + Type I isoforms).
PMO design and treatment conditions. The 25-mer PMOs were designed, synthesized and purified 
by GeneTools (Philomath, OR, USA) (Supplementary Table S1). PMOs designed to force the skipping of exons 
14 (E14) and 23a (E23a) did not require any additional analysis. However, in order to identify the proper target 
sequences for the design of PMOs forcing the inclusion of E23a, a previous bioinformatic analysis was performed. 
A sequence comprising E23a and 160 bp of the intron sequence preceding it (hg38, chr17: 31252778–31253000) 
containing a high degree of homology across species was analyzed using the online tool SpliceAid  271 to deter-
mine RNA sequences predicted to be bound by splicing proteins in humans. The SpliceAid 2 database contains 
human splicing factors expression data and RNA target motifs information. The high level of conservation of 
intronic and exonic sequences across the E23a region opened the possibility that the molecular mechanisms and 
splicing regulation were conserved between human and rat (PC12 cells). Considering the predicted binding sites 
and previously published  data11,12, we identified intronic sequences of 20–30 bp with potential regulatory prop-
erties for its inclusion and selected three of these regions, the conserved splicing regions (CSR) I, II and III, for 
the design of 25-mer complementary PMOs to sterically block the potential binding of the regulatory proteins. 
These PMOs were functionally tested in vitro.
Endo-Porter (GeneTools) was used to deliver PMOs into cells, according to the manufacturer’s instructions. 
For the PMO treatment cells were seeded at 50% of confluence. The next day, culture medium was replaced with 
fresh medium containing the indicated concentrations of PMOs. Immediately after, Endo-Porter (6 mM) was 
added and mixed. For the detection of exon 14 skipping, PC12 cells were treated with 200 μg/ml puromycin 
(Sigma) 4 h before RNA extraction to inhibit the nonsense-mediated decay (NMD) mechanism. Three biological 
replicates were done for each condition to be studied.
Differentiation assays and quantitative morphology. Phase contrast images of living PC12 cells 
were acquired with a LEICA DMI 6000B inverted microscope. At least 10 independent fields per condition were 
acquired. Cells with at least one neurite with length equal or longer to the cell body diameter were considered 
differentiated. We calculated the number of differentiated and undifferentiated cells in each field to obtain the 
percentage of differentiated cells over total cells in the field. Neurite extension was measured by determining the 
length of at least 10–20 neurites per field using the  ImageJ72 (versions 1.45 s and 1.8.0_172; https ://image j.nih.
gov/ij/downl oad.html) plugin  NeuronJ73. Neurite thickness was analyzed using  ImageJ72 (versions 1.45 s and 
1.8.0_172; https ://image j.nih.gov/ij/downl oad.html) and measured at three different neurite locations from the 
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cell body (distal, central and apical). The NADH-dehydrogenase activity assay was measured with a Cell Count-
ing Kit-8 (Dojindo), following the manufacturer’s instructions and measuring absorbance at 450 nm using a 
microplate reader (Spectra Max 34OPC, Molecular Devices). The absorbance values were normalized with the 
total number of cells per condition.
Expression levels of neuronal markers Gap43, Mmp3 and Dusp6 were analyzed by RT-qPCR using the same 
conditions as described above for Nf1, also normalized using Rpl29 and Rpl19 reference  genes70.
Immunofluorescence. Cells were grown on plastic chamber slides, fixed in 4% Paraformaldehyde, per-
meabilized with 0.1% Triton X-100 for 10 min and blocked for 15 min in 10% of Fetal Bovine Serum (FBS) in 
PBS. Cells were incubated with α-tubulin (Invitrogen, 1:1000) and NGFR (Advance Targeting systems, 1:100) 
antibodies in 1% FBS in PBS and incubated 2 h at room temperature (RT). Secondary antibody Alexa Fluor 568 
goat anti-rabbit IgG (H + L) (Invitrogen) was used at 1:1000 in PBS (10% FBS) and incubated for 45 min at RT. 
Glass cover slips were mounted with VECTASHIELD mounting medium with DAPI H-1200 (Vector Laborato-
ries). Images were taken with the confocal microscope Zeiss AxioObserver Z1.
Cell death analysis. The analysis of apoptotic cells was performed using Annexin-V-Alexa 568 antibody 
(Roche, Life technologies). In order to differentiate necrotic from positive apoptotic cells, Annexin-V staining 
was performed in combination with a DNA staining (bisbenzimide Hoechst 33258). The stained cells were ana-
lyzed by flow cytometry using BD LSRFortessa cell analyzer.
Western blot. Cells were lysed in RIPA buffer containing 150  mM NaCl, 1.0% IGEPAL  CA-630, 0.5% 
sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.0. Total protein was determined using the commercially 
available kit, Pierce BCA Protein Assay Kit (Thermo Scientific), following manufacturer’s instructions. For west-
ern blotting, the protein samples (20–30 μg) were separated by size on SDS–polyacrylamide gel, transferred into 
a PVDF membrane by electroblotting, blocked with 5% non-fat dry milk and subjected to immunoblotting with 
primary antibodies overnight at 4ºC. All antibodies used were diluted in 3% non-fat dry milk and include P-ERK 
1/2 (Cell Signalling diluted 1:2000), ERK 1/2 (Millipore diluted 1:1000), P-PKA α/β (Invitrogen diluted 1ug/
ml), PKA α/β (Termo Fisher Scientific diluted 1:500) NF1 c-terminal (Bethyl diluted 1:1000), NF1 n-terminal 
(Santa Cruz diluted 1:500) and α-Tubulin (Sigma Aldrich 1:1000). Blot was exposed to Horse Radish Peroxidase-
conjugated secondary antibody (1 h) and detected with Pierce ECL western Blotting Substrate. Band density was 
quantified using  ImageJ72 (versions 1.45 s and 1.8.0_172; https ://image j.nih.gov/ij/downl oad.html).
Statistical analysis. All functional assays to assess the effect of PMOs were repeated at least three times. 
We calculated the mean ± SEM for each biological readout and applied Student’s t-test assuming equal variances. 
An event was considered significant with a P value < 0.05. The statistical analysis was performed using PASW 
Statistics (SPSS Inc. Released 2009. PASW Statistics for Windows, Version 18.0. Chicago: SPSS Inc.; http://www.
spss.com.hk/stati stics /), while graphical representations were prepared using Prism (version 8.2.1 for MacOS X, 
GraphPad Software, San Diego, California USA; https ://www.graph pad.com/scien tific -softw are/prism /).
RNA‑seq. Total RNA extraction was performed using Maxwell 16 LEV simplyRNA Purification Kit (Pro-
mega) according to manufacturer’s instructions. Libraries were prepared starting from 200 ng of RNA per sam-
ple with the TruSeq stranded mRNA Illumina procedure. Libraries were quantified using the KAPA library 
quantitation kit for Illumina GA and sequenced on the Illumina HiSeq 2000 platform with 2 × 100 reads, 4 
samples per lane. Sequencing data was quality trimmed with Trimmomatic v0.3 then processed with TopHat v 
2.0.9, mapping with Bowtie2 against the Rattus norvergicus reference genome Rnor 6.0. The reads overlapping 
every known gene were counted and the counts matrix was processed in R. Every sample was normalized by 
the median of counts. A list of differentially expressed genes was generated per batch selecting those genes with 
a FC > 2 or FC < 0.5 and the final list was defined as the intersection of the per-batch lists. Heat map plots were 
generated with the gplots R package.
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